Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 11/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9561743 | 1.00 | CYP11B1 (0.39) | CYP11B1CYP11B2CYP2C9MEN1KMT2A | |
| SCHEMBL4659561 | 1.00 | CYP11B1 (0.39) | CYP11B1CYP11B2CYP2C9MEN1KMT2A | |
| SCHEMBL10717613 | 0.89 | MAPT (0.38) | CYP2C9MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL10515520 | 0.89 | MAPT (0.38) | CYP2C9MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL10513252 | 0.87 | MAPT (0.42) | CYP11B1CYP11B2MAPT | |
| SCHEMBL10513257 | 0.87 | MAPT (0.42) | CYP11B1CYP11B2MAPT | |
| SCHEMBL14111349 | 0.87 | MAPT (0.42) | CYP2C9MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL6664951 | 0.84 | MAPT (0.40) | CYP2C9MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL6339979 | 0.84 | KMT2A (0.42) | CYP11B1CYP11B2CYP2C9MEN1KMT2A | |
| SCHEMBL17193050 | 0.84 | KMT2A (0.42) | CYP11B1CYP11B2CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0176846-B1 | 3-AMINO-2-BENZOYL-ACRYLIC-ACID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | BAYER AG (DE) | 1989-08-16 | — | — | EP | claimed |
| US-4699992-A | 3-amino-2-benzoylacrylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1987-10-13 | — | — | US | claimed |
| EP-0176846-A2 | 3-Amino-2-benzoyl-acrylic-acid derivatives and process for their preparation | BAYER AG (DE) | 1986-04-09 | — | — | EP | claimed |
| EP-1503759-B1 | SUBSTITUTED QUINOLONE CARBOXYLIC ACIDS, THEIR DERIVATIVES, SITE OF ACTION, AND USES THEREOF | UNIV CALIFORNIA (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20080176897-A1 | Substituted Quinolone Carboxylic Acids, Their Derivatives, Site of Action, And Uses Thereof | JOHNSTONE TIMOTHY B C | 2008-07-24 | — | — | US | disclosed |
| US-20080176897-A1 | Substituted Quinolone Carboxylic Acids, Their Derivatives, Site of Action, And Uses Thereof | JOHNSTONE TIMOTHY B C | 2008-07-24 | — | — | US | disclosed |
| US-7355047-B2 | Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355047-B2 | Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-08 | — | — | US | disclosed |
| US-20060178516-A1 | Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof | OXFORD FINANCE CORPORATION | 2006-08-10 | — | — | US | disclosed |
| EP-1503759-A4 | SUBSTITUTED QUINOLONE CARBOXYLIC ACIDS, THEIR DERIVATIVES, SITE OF ACTION, AND USES THEREOF | UNIV CALIFORNIA (US) | 2006-02-15 | — | — | EP | disclosed |
| EP-1503759-A2 | SUBSTITUTED QUINOLONE CARBOXYLIC ACIDS, THEIR DERIVATIVES, SITE OF ACTION, AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003097564-A2 | SUBSTITUTED QUINOLONE CARBOXYLIC ACIDS, THEIR DERIVATIVES, SITE OF ACTION, AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-0457090-B1 | Process for the preparation of 3-amino-2 (het)aroyl-acrylic acid derivatives | BAYER AG (DE) | 1995-11-29 | — | — | EP | disclosed |
| US-5182401-A | Bactericide intermediate | BAYER AKTIENGESELLSCHAFT (DE) | 1993-01-26 | — | — | US | disclosed |
| US-5169853-A | Antibacterial agents; administering to mammals for infection | STERLING DRUG INC. (US) | 1992-12-08 | — | — | US | disclosed |
| US-5075319-A | Bactericides | STERLING DRUG INC. (US) | 1991-12-24 | — | — | US | disclosed |
| EP-0457090-A2 | Process for the preparation of 3-amino-2 (het)aroyl-acrylic acid derivatives | BAYER AG (DE) | 1991-11-21 | — | — | EP | disclosed |
| EP-0176846-B1 | 3-AMINO-2-BENZOYL-ACRYLIC-ACID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | BAYER AG (DE) | 1989-08-16 | — | — | EP | disclosed |
| US-4699992-A | 3-amino-2-benzoylacrylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1987-10-13 | — | — | US | disclosed |
| EP-0176846-A2 | 3-Amino-2-benzoyl-acrylic-acid derivatives and process for their preparation | BAYER AG (DE) | 1986-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178516-A1 | Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof | GABRB2, GABRB1, GABRB3 | CYP11B1 102/4885CYP11B2 87/4885CYP2C9 1144/4885 |
| US-20080176897-A1 | Substituted Quinolone Carboxylic Acids, Their Derivatives, Site of Action, And Uses Thereof | GABRB2, GABRB1, GABRB3 | CYP11B1 102/4885CYP11B2 87/4885CYP2C9 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.